Trial · NCT01789099
A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.
NCT01789099, Phase 1, Phase 2, Completed, Ultimovacs ASA
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer. Trials, record NCT01789099. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01789099
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.
- NCT number
- NCT01789099
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 18 participants, actual
- Lead sponsor
- Ultimovacs ASA
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- UV1 synthetic peptide vaccine and GM-CSF
- First posted
- 2013-02-11
- Last updated
- 2024-12-16
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Assessment of safety and tolerability of UV1. | up to 2 years and 3 months. | Frequency and severity of adverse events and serious adverse events. Biochemistry and hematology results, vital signs and ECOG performance status will be assessed. |
| Primary | Immunological response | Up to 2 years and 3 months. | Number of T-cell responses including time to T-cell responses (up to 6 months), level of response and duration of response. |
| Secondary | Assessment of anti tumor activity | Up to 2 years and 3 months | Tumor response and progression free survival (PFS) |
| Secondary | Selection of biological dose of peptides for further clinical trials. | Up to 2 years and 3 months | Safety profile and immunological responses of each dose level. |
| Other | Potential correlation between human cytomegalovirus status and immune response | Up to 2 years and 3 months | Determination of human cytomegalovirus (CMV) status |
| Other | Further characterization of the immune reaction triggered by the treatment. | Up to 2 years and 3 months | Extended immunological analysis. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33324397 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01789099
GET https://conductscience.org/api/trials/v1/NCT01789099/registered